David Schlessel, MD
Nuclear Cardiology · Voorhees, NJNPI 1962478826
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 93 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $686 and has fallen 55.5% since, to $305 in 2025. That places this record below the midpoint for nuclear cardiology clinicians in NJ, where the typical reported total is $3,343.
Across 93 payments — averaging $21.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$363
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$230
- Novartis$201
- Johnson & Johnson$198
- Boehringer Ingelheim$152
- Abbott$121
- plus $734 from 21 others
What the payments were for
- Food & beverage$1,998100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 22 | $363 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $230 |
| Novartis | 12 | $201 |
| Johnson & Johnson | 6 | $198 |
| Boehringer Ingelheim | 3 | $152 |
| Abbott | 1 | $121 |
| Boston Scientific | 5 | $120 |
| Pfizer | 6 | $84 |
| Sanofi-aventis U.S. LLC | 5 | $63 |
| Scpharmaceuticals Inc. | 3 | $52 |
| Edwards Lifesciences | 1 | $49 |
| Abiomed | 2 | $49 |
| Irhythm Technologies, Inc. | 2 | $35 |
| Lexicon Pharmaceuticals, Inc. | 2 | $34 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $32 |
| AstraZeneca | 2 | $30 |
| Amarin Pharma, Inc. | 2 | $27 |
| Cvrx, Inc. | 1 | $23 |
| Bayer | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Teleflex LLC | 1 | $15 |
| W. L. Gore & Associates, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,998 in reported general payments places this provider in the 25th percentile of 34 nuclear cardiology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 285 | $364,731 |
| Repatha SureclickEvolocumab | 117 | $148,591 |
| EntrestoSacubitril/Valsartan | 45 | $58,467 |
| XareltoRivaroxaban | 36 | $47,037 |
| Praluent PenAlirocumab | 36 | $44,078 |
| BrilintaTicagrelor | 18 | $22,971 |
| VascepaIcosapent Ethyl | 15 | $15,444 |
| Icosapent Ethyl | 22 | $14,676 |
| Ezetimibe | 423 | $14,035 |
| FarxigaDapagliflozin Propanediol | 12 | $13,819 |
| Metoprolol Succinate | 495 | $7,911 |
| Atorvastatin Calcium | 530 | $7,420 |
| Carvedilol ErCarvedilol Phosphate | 14 | $6,052 |
| Rosuvastatin Calcium | 369 | $5,310 |
| Ranolazine ErRanolazine | 24 | $3,657 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $84 | $364,731285 claims |
| NovartisEntresto | $201 | $58,46745 claims |
| Johnson & JohnsonXarelto | $198 | $47,03736 claims |
| AstraZenecaBrilinta, Farxiga | $30 | $36,79030 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 34 nuclear cardiology providers in New Jersey.
Other nuclear cardiology in Voorhees
- Scott GablerVoorhees$7K
- Stephen CrawfordVoorhees$1K
- Brett SealoveEatontown$410K
- Madhav UpadhyayaTinton Falls$89K
- Mark FinchCherry Hill$28K
- Hafeza ShaikhWillingboro$16K
- Nasser ChaudhryCherry Hill$11K
- Ralph RussoMoorestown$11K
- Anthony SauerweinMoorestown$10K
- Howard WeinbergSewell$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.